Attorneys at Mintz provide a comparative analysis of trade secret protections in the United States and the European Union, focusing on the submission of proprietary information to governmental agencies. Specifically, the article investigates how trade secrets are safeguarded when submitted to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), particularly in light of third-party information requests under government transparency laws.
Both the U.S. and EU have established legal frameworks aimed at ensuring the confidentiality of sensitive business information provided to regulatory bodies. However, the effectiveness and implementation of these frameworks can vary significantly between jurisdictions. The discussion highlights the potential vulnerabilities that corporations face when their confidential data is subject to public access requests, emphasizing the importance of understanding the differing legal landscapes.
For a detailed examination of these issues and further insights from legal experts, you can read the full article on Law360.